Concluding question - ATTR-ACT Trial.
Session Hot Line Session 3
Congress : ESC Congress 2018
- Topic : cardiovascular disease in special populations
- Sub-topic : Neurologic Disorders and Heart Disease
- Session type : Late-Breaking Science
Members get moreJoin now
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.